Jonathan E. Lim - 03 Feb 2025 Form 4 Insider Report for Maze Therapeutics, Inc. (MAZE)

Role
Director
Signature
/s/ Courtney Phillips, as attorney-in-fact
Issuer symbol
MAZE
Transactions as of
03 Feb 2025
Transactions value $
$0
Form type
4
Filing time
04 Feb 2025, 16:37:54 UTC
Previous filing
30 Jan 2025
Next filing
23 Jun 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MAZE Common Stock Conversion of derivative security +37,724 37,724 03 Feb 2025 City Hill, LLC F1, F2
transaction MAZE Common Stock Conversion of derivative security +270,232 +7.16% 307,956 03 Feb 2025 City Hill, LLC F2, F3
holding MAZE Common Stock 20,744 03 Feb 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MAZE Series A Preferred Stock Conversion of derivative security -363,703 -100% 0 03 Feb 2025 Common Stock 37,724 City Hill, LLC F1, F2
transaction MAZE Series B Preferred Stock Conversion of derivative security -2,231,381 -100% 0 03 Feb 2025 Common Stock 270,232 City Hill, LLC F2, F3
transaction MAZE Stock Option (Right to Buy) Award +5,704 5,704 09 Dec 2024 Common Stock 5,704 $10.42 Direct F4, F5, F6
transaction MAZE Stock Option (Right to Buy) Disposed to Issuer -5,704 -100% 0 09 Dec 2024 Common Stock 5,704 $17.74 Direct F4, F5, F6
transaction MAZE Stock Option (Right to Buy) Award $0 +9,086 $0 9,086 09 Dec 2024 Common Stock 9,086 $10.42 Direct F4, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series A Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.1037236801. The securities have no expiration date.
F2 These securities are directly held by City Hill, LLC, of which the reporting person is the managing partner.
F3 Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for- 0.1211056427. The securities have no expiration date.
F4 This transaction is an exempt transaction with the Issuer which occurred prior to the Issuer registering a class of equity securities under Section 12 of the Securities Exchange Act of 1934, as amended. It is reported herein as a transaction pursuant to Rule 16a-2(a). All numbers of shares and exercise prices have been adjusted to reflect a 1:9.641 reverse stock split of the Issuer's Common Stock effected on January 24, 2025.
F5 The option vested or vests as to 1/36th of the total award monthly, with the first tranche vesting on April 1, 2023, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
F6 This option, which was first granted on March 9, 2023, was canceled and exchanged for a new option having a lower exercise price in connection with an option repricing approved by the Issuer's Board of Directors on December 9, 2024. All terms of the option remained unchanged other than the exercise price.
F7 The option vested or vests as to 1/36th of the total award monthly, with the first tranche vesting on January 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.